Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
Description of Eptifibatide Acetate :Appearance :White powder
Specific Optical Rotation(c=1,HAc,By Anhydrous, Acetic Acid-free) :-78~-88°
Water Content(Karl Fischer) :≤8.0%
Acetate Content(by HPLC) :≤15.0%
Amino Acid Composition :±10% of theoretical
Purity (by HPLC) :≥98.0%
Single Impurity(by HPLC) :≤1.0%
Peptide Content(by %N) :≥80%
Assay(By Anhydrous, Acetic Acid-free ) :95.0~105.0%
Bacterial Endotoxins :≤5EU/mg
Integrilin is sold in two strengths, globally: vials containing 2 mg/ml (20 mg totally) and 0.75 mg/ml (75 mg totally). A third size is sold in the US: 100 ml vials containing 2 mg/ml (200 mg totally).
Read More: buy Eptifibatide Acetate
No comments:
Post a Comment